Eosinophilic Disorders Market is Rising with Biologic Drug Approvals and Increasing Autoimmune Cases|Key Players: Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A

The global eosinophilic disorders market reached US$ 150 million in 2023 and is expected to reach US$ 278 million by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.

The latest Eosinophilic Disorders Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/eosinophilic-disorders-market?ophp

Eosinophilic disorders involve abnormal accumulation of eosinophils, leading to inflammation and tissue damage in organs such as the lungs, skin, and gastrointestinal tract. The market is expanding due to increasing prevalence, improved diagnostic capabilities, and development of targeted biologic therapies like IL-5 and IL-13 inhibitors.

Eosinophilic Disorders Market Competitors Overview:

Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., and Hikma Pharmaceuticals among others.

Important Industry Updates of 2024 and 2025:

1. On March 24, 2025, the European Medicines Agency accepted GSK's application to expand Nucala (mepolizumab) to treat eosinophilic COPD, following trials demonstrating a reduction in exacerbations compared to placebo.

2. On May 7, 2025, the FDA's Prescription Drug User Fee Act (PDUFA) date was set for the regulatory review of mepolizumab as an add-on therapy for eosinophilic COPD patients.

3. On May 22, 2025, the FDA officially approved Nucala as an add-on maintenance treatment for adult patients with eosinophilic COPD.

4. On April 21, 2025, the FDA granted Orphan Drug Designation to NS 229, a selective JAK1 inhibitor, for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

5. In January 2025, a meta-analysis confirmed the FDA approval of benralizumab (Fasenra) in September 2024 for EGPA, highlighting its steroid-sparing effects and strong remission rates.

Eosinophilic Disorders Market Segments Overview:

∎ By Type (Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis, Hypereosinophilic Syndrome)
∎ By Treatment (Medications, Dietary Therapy, Dilation, Others)
∎ By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/eosinophilic-disorders-market?ophp

Methodology and Scope:

This Eosinophilic Disorders Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.

Regional Overview for Eosinophilic Disorders Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=eosinophilic-disorders-market?ophp

The Report Includes:

âž¡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
âž¡ Go-to-market Strategy.
âž¡ Neutral perspective on the market performance.
âž¡ Customized regional/country reports as per request and country level analysis.
âž¡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➤ What are the global sales, production, import, and export trends in the Eosinophilic Disorders market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the Eosinophilic Disorders market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.